Cover
Cover - shares | 6 Months Ended | |
Jun. 30, 2021 | Aug. 16, 2021 | |
Cover [Abstract] | ||
Entity Registrant Name | SANARA MEDTECH INC. | |
Entity Central Index Key | 0000714256 | |
Document Type | 10-Q | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Small Business | true | |
Entity Shell Company | false | |
Entity Emerging Growth Company | false | |
Entity Current Reporting Status | Yes | |
Document Period End Date | Jun. 30, 2021 | |
Entity Filer Category | Non-accelerated Filer | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2021 | |
Entity Common Stock Shares Outstanding | 7,626,705 | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity File Number | 001-39678 | |
Entity Incorporation State Country Code | TX | |
Entity Tax Identification Number | 59-2219994 | |
Entity Address Address Line 1 | 1200 Summit Ave | |
Entity Address Address Line 2 | Suite 414 | |
Entity Address City Or Town | Fort Worth | |
Entity Address State Or Province | TX | |
Entity Address Postal Zip Code | 76102 | |
City Area Code | 817 | |
Local Phone Number | 529-2300 | |
Security 12b Title | Common Stock, $0.001 par value | |
Trading Symbol | SMTI | |
Security Exchange Name | NASDAQ | |
Entity Interactive Data Current | Yes |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Current assets | ||
Cash | $ 24,389,004 | $ 455,366 |
Accounts receivable, net of allowances of $138,417 and $100,189 | 2,445,225 | 2,217,533 |
Royalty receivable | 49,344 | 49,344 |
Inventory, net of allowance for obsolescence of $295,841 and $276,603 | 1,538,398 | 1,148,253 |
Prepaid and other assets | 497,110 | 611,817 |
Total current assets | 28,919,081 | 4,482,313 |
Long-term assets | ||
Property, plant and equipment, net of accumulated depreciation of $159,732 and $124,691 | 1,668,994 | 678,589 |
Right of use assets - operating leases | 406,024 | 467,653 |
Intangible assets, net of accumulated amortization of $983,466 and $827,108 | 3,785,187 | 3,097,666 |
Investment in equity securities | 4,005,374 | 1,100,000 |
Total long-term assets | 9,865,579 | 5,343,908 |
Total assets | 38,784,660 | 9,826,221 |
Current liabilities | ||
Accounts payable | 313,569 | 271,251 |
Accounts payable - related parties | 57,507 | 223,589 |
Accrued royalties and expenses | 527,518 | 502,191 |
Accrued bonus and commissions | 2,719,258 | 2,417,277 |
Operating lease liability - current | 128,301 | 125,587 |
Total current liabilities | 3,746,153 | 3,539,895 |
Long-term liabilities | ||
Operating lease liability - long term | 290,751 | 355,797 |
Other long-term liabilities | 90,293 | 90,293 |
Total long-term liabilities | 381,044 | 446,090 |
Total liabilities | 4,127,197 | 3,985,985 |
Shareholders' equity | ||
Common Stock: $0.001 par value, 20,000,000 shares authorized; 7,612,336 issued and outstanding as of June 30, 2021 and 6,297,008 issued and outstanding as of December 31, 2020 | 7,612 | 6,297 |
Additional paid-in capital | 44,487,958 | 13,176,576 |
Accumulated deficit | (9,385,478) | (7,032,242) |
Total Sanara MedTech shareholders' equity | 35,110,092 | 6,150,631 |
Equity attributable to noncontrolling interest | (452,629) | (310,395) |
Total shareholders' equity | 34,657,463 | 5,840,236 |
Total liabilities and shareholders' equity | $ 38,784,660 | $ 9,826,221 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
CONSOLIDATED BALANCE SHEETS | ||
Accounts receivable, net of allowance for bad debt | $ 138,417 | $ 100,189 |
Inventory, net of allowance for obsolescence | 295,841 | 276,603 |
Property plant and equipment accumulated amortization | 159,732 | 124,691 |
Intangible asset accumulated amortization | $ 983,466 | $ 827,108 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 20,000,000 | 20,000,000 |
Common stock, shares issued | 7,612,336 | 6,297,008 |
Common stock, shares outstanding | 7,612,336 | 6,297,008 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||||
Net Revenue | $ 6,277,133 | $ 2,967,183 | $ 11,286,569 | $ 6,491,514 |
Cost of goods sold | 536,405 | 348,675 | 1,010,838 | 678,863 |
Gross profit | 5,740,728 | 2,618,508 | 10,275,731 | 5,812,651 |
Operating expenses | ||||
Selling, general and administrative expenses | 6,562,144 | 3,582,511 | 11,971,874 | 8,514,662 |
Research and development | 103,981 | 41,516 | 222,193 | 45,903 |
Depreciation and amortization | 100,807 | 74,221 | 191,398 | 127,726 |
Total operating expenses | 6,766,932 | 3,698,248 | 12,385,465 | 8,688,291 |
Operating loss | (1,026,204) | (1,079,740) | (2,109,734) | (2,875,640) |
Other expense | ||||
Other expense | 0 | (48,716) | 0 | (85,474) |
Interest expense | 0 | (1,101) | (711) | (9,455) |
Share of losses from equity method investment | (179,769) | 0 | (278,904) | 0 |
Total other expense | (179,769) | (49,817) | (279,615) | (94,929) |
Net loss | (1,205,973) | (1,129,557) | (2,389,349) | (2,970,569) |
Less: Net loss attributable to noncontrolling interest | (34,481) | (3,793) | (36,113) | (7,848) |
Net loss attributable to Sanara MedTech common shareholders | $ (1,171,492) | $ (1,125,764) | $ (2,353,236) | $ (2,962,721) |
Net loss per share of common stock, basic and diluted | $ (0.16) | $ (0.18) | $ (0.33) | $ (0.54) |
Weighted average number of common shares outstanding, basic and diluted | 7,496,604 | 6,203,577 | 7,158,503 | 5,477,759 |
CONSOLIDATED STATEMENTS OF CHAN
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (UNAUDITED) - USD ($) | Total | Preferred Stock Series F | Common Stock | Additional Paid-In Capital | Accumulated Income/(Deficit) | Noncontrolling Interest |
Balance, shares at Dec. 31, 2019 | 1,136,815 | 3,571,001 | ||||
Balance, amount at Dec. 31, 2019 | $ 6,392,400 | $ 11,368,150 | $ 3,571 | $ (2,081,829) | $ (2,675,802) | $ (221,690) |
Conversion of Preferred Shares to Common Stock, shares | (1,136,815) | 2,273,630 | ||||
Conversion of Preferred Shares to Common Stock, amount | 0 | $ (11,368,150) | $ 2,274 | 11,365,876 | 0 | 0 |
Conversion of Promissory Note to Common Stock, shares | 179,101 | |||||
Conversion of Promissory Note to Common Stock, amount | 1,611,911 | 0 | $ 179 | 1,611,732 | 0 | 0 |
Share-based compensation, shares | 180,100 | |||||
Share-based compensation, amount | 393,740 | 0 | $ 180 | 393,560 | 0 | 0 |
Net loss | (1,841,012) | 0 | $ 0 | (1,836,957) | (4,055) | |
Balance, shares at Mar. 31, 2020 | 6,203,832 | |||||
Balance, amount at Mar. 31, 2020 | 6,557,039 | $ 0 | $ 6,204 | 11,289,339 | (4,512,759) | (225,745) |
Balance, shares at Dec. 31, 2019 | 1,136,815 | 3,571,001 | ||||
Balance, amount at Dec. 31, 2019 | 6,392,400 | $ 11,368,150 | $ 3,571 | (2,081,829) | (2,675,802) | (221,690) |
Net loss | (2,970,569) | |||||
Balance, shares at Jun. 30, 2020 | 6,203,402 | |||||
Balance, amount at Jun. 30, 2020 | 5,613,653 | 0 | $ 6,203 | 11,475,511 | (5,638,523) | (229,538) |
Balance, shares at Mar. 31, 2020 | 6,203,832 | |||||
Balance, amount at Mar. 31, 2020 | 6,557,039 | 0 | $ 6,204 | 11,289,339 | (4,512,759) | (225,745) |
Share-based compensation, shares | (430) | |||||
Share-based compensation, amount | 186,171 | 0 | $ (1) | 186,172 | 0 | 0 |
Net loss | (1,129,557) | 0 | $ 0 | (1,125,764) | (3,793) | |
Balance, shares at Jun. 30, 2020 | 6,203,402 | |||||
Balance, amount at Jun. 30, 2020 | 5,613,653 | 0 | $ 6,203 | 11,475,511 | (5,638,523) | (229,538) |
Balance, shares at Dec. 31, 2020 | 6,297,008 | |||||
Balance, amount at Dec. 31, 2020 | 5,840,236 | $ 6,297 | 13,176,576 | (7,032,242) | (310,395) | |
Share-based compensation, shares | 4,744 | |||||
Share-based compensation, amount | 325,518 | 0 | $ 5 | 325,513 | 0 | 0 |
Net loss | (1,183,376) | 0 | $ 0 | 0 | (1,181,744) | (1,632) |
Issuance of common stock for asset acquisitions, shares | 50,370 | |||||
Issuance of common stock for asset acquisitions, amount | 1,750,000 | 0 | $ 50 | 1,749,950 | 0 | 0 |
Issuance of common stock in equity offering, shares | 1,265,000 | |||||
Issuance of common stock in equity offering, amount | 28,939,257 | 0 | $ 1,265 | 28,937,992 | 0 | 0 |
Distribution to noncontrolling interest member | (200,000) | 0 | $ 0 | 0 | 0 | (200,000) |
Balance, shares at Mar. 31, 2021 | 7,617,122 | |||||
Balance, amount at Mar. 31, 2021 | 35,471,635 | 0 | $ 7,617 | 44,190,031 | (8,213,986) | (512,027) |
Balance, shares at Dec. 31, 2020 | 6,297,008 | |||||
Balance, amount at Dec. 31, 2020 | 5,840,236 | $ 6,297 | 13,176,576 | (7,032,242) | (310,395) | |
Net loss | (2,389,349) | |||||
Balance, shares at Jun. 30, 2021 | 7,612,336 | |||||
Balance, amount at Jun. 30, 2021 | 34,657,463 | $ 7,612 | 44,487,958 | (9,385,478) | (452,629) | |
Balance, shares at Mar. 31, 2021 | 7,617,122 | |||||
Balance, amount at Mar. 31, 2021 | 35,471,635 | 0 | $ 7,617 | 44,190,031 | (8,213,986) | (512,027) |
Share-based compensation, shares | (4,786) | |||||
Share-based compensation, amount | 297,922 | 0 | $ (5) | 297,927 | 0 | 0 |
Net loss | (1,205,973) | 0 | 0 | (1,171,492) | (34,481) | |
Capital contribution of noncontrolling interest member | 93,879 | $ 0 | $ 0 | 0 | 0 | 93,879 |
Balance, shares at Jun. 30, 2021 | 7,612,336 | |||||
Balance, amount at Jun. 30, 2021 | $ 34,657,463 | $ 7,612 | $ 44,487,958 | $ (9,385,478) | $ (452,629) |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Cash flows from operating activities: | ||
Net loss | $ (2,389,349) | $ (2,970,569) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Depreciation and amortization | 191,398 | 127,726 |
Interest expense on convertible debt | 0 | 8,354 |
Interest expense on PPP loan | 0 | 1,101 |
Loss on disposal of asset | 0 | 2,180 |
Bad debt expense | 51,536 | 30,000 |
Inventory obsolescence | 29,834 | 75,422 |
Share-based compensation | 623,440 | 491,069 |
Noncash lease expense | 61,629 | 57,880 |
Loss on equity method investment | 278,904 | 0 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (279,229) | (112,301) |
Inventory | (419,979) | (191,595) |
Prepaid - related parties | 0 | (50,970) |
Prepaid and other assets | 114,707 | (310,666) |
Accounts payable | 42,318 | (197,709) |
Accounts payable - related parties | (166,081) | (66,346) |
Accrued royalties and expenses | 25,327 | 333,731 |
Accrued liabilities | 239,650 | 40,502 |
Net cash used in operating activities | (1,595,895) | (2,732,191) |
Cash flows from investing activities: | ||
Purchase of property and equipment | (25,446) | (57,456) |
Purchase of intangible assets | 0 | (1,100,000) |
Investment in equity securities | (3,184,278) | 0 |
Net cash used in investing activities | (3,209,724) | (1,157,456) |
Cash flows from financing activities: | ||
Draw on line of credit | 800,000 | 0 |
Pay off line of credit | (800,000) | 0 |
Proceeds from PPP Loan | 0 | 583,000 |
Public offering net proceeds | 28,939,257 | 0 |
Distribution to noncontrolling interest shareholders | (200,000) | 0 |
Net cash provided by financing activities | 28,739,257 | 583,000 |
Net increase (decrease) in cash | 23,933,638 | (3,306,647) |
Cash, beginning of period | 455,366 | 6,611,928 |
Cash, end of period | 24,389,004 | 3,305,281 |
Cash paid during the period for: | ||
Interest | 711 | 0 |
Income taxes | 0 | 0 |
Supplemental noncash investing and financing activities: | ||
Common stock issued for conversion of Series F Preferred Stock | 0 | 11,368,150 |
Common stock issued for conversion of related party debt and interest | 0 | 1,611,911 |
Common stock issued for asset acquisitions | 1,750,000 | 750,000 |
License agreement as capital contribution from noncontrolling interest member | $ 93,879 | $ 0 |
NATURE OF BUSINESS AND BACKGROU
NATURE OF BUSINESS AND BACKGROUND | 6 Months Ended |
Jun. 30, 2021 | |
NATURE OF BUSINESS AND BACKGROUND | |
NOTE 1 - NATURE OF BUSINESS AND BACKGROUND | NOTE 1 – NATURE OF BUSINESS AND BACKGROUND Sanara MedTech Inc. (“we”, “our”, the “Company”) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical and chronic wound and skin care markets. The Company’s portfolio of products and services is designed to allow us to deliver comprehensive wound and skin care solutions for patients in all care settings, including acute (hospitals and long-term acute care hospitals) and post-acute (wound care clinics, physician offices, skilled nursing facilities (“SNFs”), home health, hospice, and retail). Each of the Company’s products, services, and technologies contributes to the Company’s overall goal of achieving better clinical outcomes at a lower overall cost for patients regardless of where they receive care. The Company strives to be one of the most innovative and comprehensive providers of effective wound and skin care products and technologies. Impact of the COVID-19 Pandemic Beginning in March 2020, many states issued orders suspending elective surgeries in order to free-up hospital resources to treat COVID-19 patients. This resulted in a reduction in demand for the Company’s surgical products beginning in the second half of March 2020. Additionally, most states limited access to SNFs to only resident caregivers, which impeded the Company’s ability to provide education and product training to the clinicians who use the Company’s products in these facilities. These restrictions resulted in an overall decline in sales for the second quarter of 2020. During the second half of 2020 and the first half of 2021, the Company saw a strong rebound in product sales as restrictions on elective surgeries eased in its primary markets in Texas, Florida, and the southeastern United States. Due to recent COVID-19 resurgences and variants, the duration and effects of the pandemic remain uncertain; however, management believes that elective surgical procedures will continue to be performed with the exception of certain geographic hotspots. The Company continues to closely monitor the pandemic in order to ensure the safety of the Company’s people and its ability to serve its customers and patients. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended |
Jun. 30, 2021 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2 -- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. Certain prior period amounts in the consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation. In the opinion of management of the Company, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six-month period ended June 30, 2021, are not necessarily indicative of the results that may be expected for the year ending December 31, 2021, or any other period. These financial statements and notes should be read in conjunction with the financial statements for each of the two years ended December 31, 2020, and December 31, 2019, included in the Company’s most recent Annual Report on Form 10-K. Principles of Consolidation The accompanying unaudited consolidated financial statements include the accounts of Sanara MedTech Inc., its wholly-owned and majority-owned subsidiaries, as well as other entities in which the Company has a controlling financial interest. All significant intercompany profits, losses, transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and determined there was not a material impact on the Company’s estimates and assumptions used in preparing the unaudited consolidated financial statements as of and for the six months ended June 30, 2021. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Income / Loss Per Share The Company computes income per share in accordance with Accounting Standards Codification (“ASC”) Topic 260, Earnings per Share, which requires the Company to present basic and dilutive income per share when the effect is dilutive. Basic income per share is computed by dividing income available to common shareholders by the weighted average number of shares of common stock outstanding. Diluted income per share is computed similar to basic income per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. All common stock equivalents were excluded from the current and prior period calculations, as their inclusion would have been anti-dilutive during the three and six months ended June 30, 2021 and 2020 due to the Company’s net loss. The following table summarizes the shares of common stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the three and six months ended June 30, 2021 and 2020 as such shares would have had an anti-dilutive effect: As of June 30, 2021 2020 Stock options 11,500 11,500 Unvested restricted stock 115,719 154,090 Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), which the Company adopted on January 1, 2018 using the modified retrospective method. Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for transferring those goods or services. Revenue is recognized based on the following five step model: - Identification of the contract with a customer - Identification of the performance obligations in the contract - Determination of the transaction price - Allocation of the transaction price to the performance obligations in the contract - Recognition of revenue when, or as, the Company satisfies a performance obligation Details of this five-step process are as follows: Identification of the contract with a customer Customer purchase orders are generally considered to be contracts under ASC 606. Purchase orders typically identify specific terms of products to be delivered, create the enforceable rights and obligations of both parties, and result in commercial substance. No other forms of contract revenue recognition, such as the completed contract or percentage of completion methods, were utilized by the Company in either 2020 or 2021. Performance obligations The Company’s performance obligation is generally limited to delivery of the requested items to its customers at the agreed upon quantities and prices. Determination and allocation of the transaction price The Company has established prices for its products. These prices are effectively agreed to when customers place purchase orders with the Company. Rebates and discounts, if any, are recognized in full at the time of sale as a reduction of net revenue. Allocation of transaction prices is not necessary where one performance obligation exists. Recognition of revenue as performance obligations are satisfied Product revenues are recognized when the products are delivered, and control of the goods and services passes to the customer. Disaggregation of Revenue Revenue streams from product sales and royalties are summarized below for the six months ended June 30, 2021 and 2020. All revenue was generated in the United States; therefore, no geographical disaggregation was necessary. Six Months Ended June 30, 2021 2020 Product sales revenue $ 11,186,069 $ 6,391,014 Royalty revenue 100,500 100,500 Total Revenue $ 11,286,569 $ 6,491,514 The Company recognizes royalty revenue from a development and licensing agreement between BioStructures, LLC and the Company. The Company records revenue each calendar quarter as earned per the terms of the agreement which stipulates that the Company will receive quarterly royalty payments of at least $50,250. Under the terms of the development and license agreement, royalties of 2.0% are recognized on sales of products containing the Company’s patented resorbable bone hemostasis. The minimum annual royalty due to the Company is $201,000 per year throughout the life of the patent which expires in 2023. These royalties are payable in quarterly installments of $50,250. To date, royalties related to this development and licensing agreement have not exceeded the annual minimum of $201,000 ($50,250 per quarter). Contract Assets and Liabilities The Company does not have any contract assets or contract liabilities. Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure accounts receivable are not overstated due to uncollectible accounts. The Company recorded bad debt expense of $51,536 and $30,000during the six months ended June 30, 2021 and 2020, respectively. The allowance for doubtful accounts was $120,273 at June 30, 2021 and $64,989 at December 31, 2020. Bad debt reserves are maintained based on a variety of factors, including the length of time receivables are past due and a detailed review of certain individual customer accounts. The Company also establishes other allowances to ensure accounts receivable are not overstated due to customer rebates and product returns. These allowances totaled $18,144 at June 30, 2021 and $35,200 at December 31, 2020. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. The Company considered the impact of COVID-19 in its analysis of receivables and determined its accounts receivable allowances were appropriate at June 30, 2021. Inventories Inventories are stated at the lower of cost or net realizable value, with cost computed on a first-in, first-out basis. Inventories consist of finished goods and related packaging components. The Company recorded inventory obsolescence expense of $29,834 the six months ended June 30, 2021 and $75,422 the six months ended June 30, 2020. The allowance for obsolete and slow-moving inventory had a balance of $295,841 at June 30, 2021, and $276,603 at December 31, 2020. The Company considered the impact of COVID-19 on its recorded value of inventory and determined no adjustment was necessary as of June 30, 2021. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets, ranging from three to ten years. Below is a summary of property and equipment for the periods presented: June 30, December 31, 2021 2020 Computers $ 98,140 $ 87,252 Office equipment 22,598 22,597 Furniture and fixtures 209,746 205,871 Leasehold improvements 2,030 2,030 Internal use software 1,485,530 485,530 Capital in progress 10,682 - 1,828,726 803,280 Less accumulated depreciation (159,732 ) (124,691 ) Property and equipment, net $ 1,668,994 $ 678,589 Depreciation expense related to property and equipment was $35,040 for the six months ended June 30, 2021, and $33,227 for the six months ended June 30, 2020. The Company considered the impact the COVID-19 pandemic may have had on the carrying value of its property and equipment and determined that no impairment loss had occurred as of June 30, 2021. The Company will continue to assess the COVID-19 pandemic’s impact on its business including any indicators of impairment of property and equipment. Internal Use Software The Company accounts for costs incurred to develop computer software for internal use in accordance with ASC Topic 350-40, Intangibles – Goodwill and Other. The Company capitalizes the costs incurred during the application development stage, which generally includes third-party developer fees to design the software configuration and interfaces, coding, installation, and testing. The Company begins capitalization of qualifying costs when both the preliminary project stage is completed, and management has authorized further funding for the completion of the project. Costs incurred during the preliminary project stage along with post implementation stages of internal-use computer software are expensed as incurred. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized development costs are classified as property and equipment, net in the consolidated balance sheets and are amortized over the estimated useful life of the software, which is generally five to seven years. Intangible Assets Intangible assets are stated at cost of acquisition less accumulated amortization and impairment loss, if any. Cost of acquisition includes purchase price and any cost directly attributable to bringing the asset to its working condition for the intended use. The Company amortizes its intangible assets on a straight-line basis over the useful life of the respective assets which is generally the life of the related patents (if applicable). See Note 3 Impairment of Long-Lived Assets Long-lived assets, including certain identifiable intangibles held and to be used by the Company, are reviewed for impairment whenever events or changes in circumstances, including the COVID-19 pandemic, indicate that the carrying amount of such assets may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows and the estimated liquidation value of such long-lived assets and provides for impairment if such undiscounted cash flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market values, undiscounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value. No impairment was recorded during the six months ended June 30, 2021 and 2020. Investments in Equity Securities The Company’s equity investments consist of non-marketable equity securities in privately held companies without readily determinable fair values, and are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The Company applies the equity method of accounting to investments when it has significant influence, but not controlling interest, in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “Share of losses from equity method investment” in our consolidated statements of operations. The Company’s equity method investments are adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the consolidated statements of cash flows. The Company has reviewed the carrying value of its investments and has determined there was no impairment or observable price changes as of June 30, 2021. Fair Value Measurement As defined in ASC Topic 820, Fair Value Measurement (“ASC 820”), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis. Income Taxes Income taxes are accounted for under the asset and liability method, whereby deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. Advertising Expense In accordance with ASC Topic No. 720-35-25-1, the Company recognizes advertising expenses the first time the advertising takes place. Advertising expenses are expensed as incurred. Share-based Compensation The Company accounts for stock-based compensation to employees and nonemployees in accordance with Accounting Standards Update (“ASU”) 2018-07 Topic 718. Stock-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as expense over the stipulated vesting period, if any. The Company estimates the fair value of stock-based payments using the Black-Scholes option-pricing model for common stock options and warrants, and the closing price of the Company’s common stock for common stock issuances. Research and Development Costs Research and development expenses include costs for contracted services related to improvements to manufacturing processes, enhancements to the Company’s currently available products, and additional investments in the product and platform development pipeline. The Company expenses research and development costs as incurred. Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board issued ASU 2019-12, Simplifications to Accounting for Income Taxes, which removes certain exceptions to the general principles of Topic 740 and adds guidance to reduce complexity in accounting for income taxes. The ASU is effective for annual and interim periods in fiscal years beginning December 15, 2020. The adoption of this standard did not have a material effect on the Company’s consolidated financial statements. |
INTANGIBLE ASSETS
INTANGIBLE ASSETS | 6 Months Ended |
Jun. 30, 2021 | |
INTANGIBLE ASSETS | |
NOTE 3 - INTANGIBLE ASSETS | NOTE 3 – INTANGIBLE ASSETS The carrying values of the Company’s finite-lived intangible assets were as follows: June 30, 2021 December 31, 2020 Accumulated Accumulated Cost Amortization Net Cost Amortization Net Product Licenses $ 4,193,879 $ (417,519 ) $ 3,776,360 $ 3,350,000 $ (264,909 ) $ 3,085,091 Patent 510,310 (510,310 ) - 510,310 (510,310 ) - Software and Other 64,464 (55,637 ) 8,827 64,464 (51,889 ) 12,575 Total $ 4,768,653 $ (983,466 ) $ 3,785,187 $ 3,924,774 $ (827,108 ) $ 3,097,666 In March 2021, the Company issued 20,834 shares of its common stock to Rochal Industries, LLC (“Rochal”) for a $750,000 milestone payment required per the terms of a licensing agreement with Rochal. The payment became due upon the Company’s public offering of common stock in February 2021. The milestone payment was recorded as an addition to intangible assets. As of June 30, 2021, the weighted-average amortization period for all intangible assets was 12.4 years. Amortization expense related to intangible assets was $156,358 for the six months ended June 30, 2021 and $94,499 for the six months ended June 30, 2020. The estimated remaining amortization expense as of June 30, 2021 is as follows: Remainder of 2021 $ 172,769 2022 343,123 2023 338,043 2024 338,043 2025 338,043 Thereafter 2,255,166 Total $ 3,785,187 The Company has reviewed the carrying value of intangible assets due to the events and circumstances surrounding the COVID-19 pandemic. The Company does not believe the impact of COVID-19 has created an impairment loss on the Company’s intangible assets as of June 30, 2021. Accordingly, there was no impairment loss recognized on the Company’s intangible assets during the six months ended June 30, 2021. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 6 Months Ended |
Jun. 30, 2021 | |
COMMITMENTS AND CONTINGENCIES | |
NOTE 4 - COMMITMENTS AND CONTINGENCIES | NOTE 4 - COMMITMENTS AND CONTINGENCIES License Agreements and Royalties CellerateRX® Activated Collagen® On August 27, 2018, the Company entered into an exclusive, world-wide sublicense agreement with CGI Cellerate RX, LLC (“CGI Cellerate RX”) to distribute CellerateRX Surgical and HYCOL products into the wound care and surgical markets. Pursuant to the sublicense agreement, the Company pays royalties of 3-5% of annual collected net sales of CellerateRX Surgical and HYCOL. As amended on January 26, 2021, the term of the sublicense extends through May 2050, with automatic successive year-to-year renewal terms thereafter so long as the Company’s Net Sales (as defined in the sublicense agreement) each year are equal to or in excess of $1,000,000. If the Company’s Net Sales fall below $1,000,000 for any year after the initial expiration date, CGI Cellerate RX will have the right to terminate the sublicense agreement upon written notice. Minimum royalties of $400,000 per year are payable for the first five years of the sublicense agreement. For the six months ended June 30, 2021 and 2020, royalty expense accrued under the terms of this agreement totaled $404,220 and $210,220, respectively. BIAKŌS Antimicrobial Wound Gel and BIAKŌS Antimicrobial Skin and Wound Cleanser On July 7, 2019, the Company executed a license agreement with Rochal, a related party, whereby the Company acquired an exclusive world-wide license to market, sell and further develop antimicrobial products for the prevention and treatment of microbes on the human body utilizing certain Rochal patents and pending patent applications (the “BIAKŌS License Agreement”). Currently, the products covered by the BIAKŌS License Agreement are BIAKŌS Antimicrobial Wound Gel and BIAKŌS Antimicrobial Skin and Wound Cleanser. Both products are 510(k) approved. The Company’s Executive Chairman is a director of Rochal, and indirectly a significant shareholder of Rochal, and through the potential exercise of warrants, a majority shareholder of Rochal. Another one of the Company’s directors is also a director and significant shareholder of Rochal. Recent and future commitments under the terms of the BIAKŌS License Agreement include: ● In March 2021, the Company issued 20,834 shares of its common stock to Rochal as full payment of a $750,000 milestone which became due upon the Company’s public offering of common stock in February 2021. ● The Company pays Rochal a royalty of 2-4% of net sales. The minimum annual royalty due to Rochal was $100,000 in 2020 and will increase by 10% each subsequent calendar year up to a maximum amount of $150,000. ● The Company pays additional royalty annually based on specific net profit targets from sales of the licensed products, subject to a maximum of $1,000,000 during any calendar year. Unless previously terminated by the parties, the BIAKŌS License Agreement expires with the related patents in December 2031. For the six months ended June 30, 2021 and 2020, royalty expense recognized under this agreement was $55,000 and $50,000, respectively. CuraShield Antimicrobial Barrier Film and No Sting Skin Protectant On October 1, 2019, the Company executed a license agreement with Rochal pursuant to which the Company acquired an exclusive world-wide license to market, sell and further develop certain antimicrobial barrier film and skin protectant products for use in the human health care market utilizing certain Rochal patents and pending patent applications (the “ABF License Agreement”). Currently, the products covered by the ABF License Agreement are CuraShield Antimicrobial Barrier Film and a no sting skin protectant product. Future commitments under the terms of the ABF License Agreement include: ● The Company will pay Rochal a royalty of 2-4% of net sales. The minimum annual royalty due to Rochal will be $50,000 beginning with the first full calendar year following the year in which first commercial sales of the products occur. The annual minimum royalty will increase by 10% each subsequent calendar year up to a maximum amount of $75,000. ● The Company will pay additional royalties annually based on specific net profit targets from sales of the licensed products, subject to a maximum of $500,000 during any calendar year. Unless previously terminated or extended by the parties, the ABF License Agreement will terminate upon expiration of the last U.S. patent in October 2033. No commercial sales or royalties have been recognized under this agreement as of June 30, 2021. Debrider License Agreement On May 4, 2020, the Company executed a product license agreement with Rochal, pursuant to which the Company acquired an exclusive world-wide license to market, sell and further develop a debrider for human medical use to enhance skin condition or treat or relieve skin disorders, excluding uses primarily for beauty, cosmetic, or toiletry purposes (the “Debrider License Agreement”). Future commitments under the terms of the Debrider License Agreement include: ● At the time Rochal issues a purchase order to its contract manufacturer for the first good manufacturing practice run of the licensed products, the Company will pay Rochal $600,000 in cash. ● Upon FDA clearance of the licensed products, the Company will pay Rochal $500,000 in cash and $1,000,000, which at the Company’s option may be paid in any combination of cash and its common stock. ● The Company will pay Rochal a royalty of 2-4% of net sales. The minimum annual royalty due to Rochal will be $100,000 beginning with the first full calendar year following the year in which first commercial sales of the licensed products occur and increase by 10% each subsequent calendar year up to a maximum amount of $150,000. ● The Company will pay additional royalty annually based on specific net profit targets from sales of the licensed products, subject to a maximum of $1,000,000 during any calendar year. Unless previously terminated or extended by the parties, the Debrider License Agreement will expire in October 2034. No commercial sales or royalties have been recognized under this agreement as of June 30, 2021. Resorbable Bone Hemostat The Company acquired a patent in 2009 for a resorbable bone hemostat and delivery system for orthopedic bone void fillers. This patent is not part of the Company’s long-term strategic focus. The Company subsequently licensed the patent to a third party to market a bone void filler product for which the Company receives a 3% royalty on product sales over the life of the patent, which expires in 2023, with annual minimum royalties of $201,000. The Company pays two unrelated third parties a combined royalty equal to 8% of the Company’s net revenues or minimum royalties generated from products that utilize the Company’s acquired patented bone hemostat and delivery system. To date, royalties received by the Company related to this licensing agreement have not exceeded the annual minimum of $201,000 ($50,250 per quarter). Therefore, the Company’s annual royalty obligation under the terms of the license agreement has been $16,080 ($4,020 per quarter). Other Commitments At the time of the formation of Sanara Pulsar, it and Wound Care Solutions, Limited (“WCS”), entered into a supply agreement whereby Sanara Pulsar became the exclusive distributor in the United States of certain wound care products that utilize intellectual property developed and owned by WCS. In 2019, the Company advanced to WCS $200,000 and recorded the payment as a reduction of non-controlling interests. In the event WCS’s Form K-l from Sanara Pulsar for the year 2020 does not allocate to WCS net income of at least $200,000 (the “Target Net Income”), then Cellerate, LLC will, within 30 days after such determination, pay WCS the amount of funds representing the difference between the Target Net Income and the actual amount of net income shown on WCS’s Form K-1 for the year 2020. In March 2021, the Company paid WCS $200,000 for the year 2020. For each of the years 2021 through 2024 the Target Net Income will increase by 10%, and in the event WCS’s Form K-1 for any of those years does not allocate to WCS net income in an amount at least equal to the Target Net Income for such year, then Cellerate, LLC will, within 30 days after such determination, pay WCS the amount of funds representing the difference between the Target Net Income and the actual amount of net income shown on WCS’s Form K-1 for the applicable year. All other distributions made by Sanara Pulsar to its members, not including tax distributions, will be made exclusively to Cellerate, LLC until such time as Cellerate, LLC has received an amount of distributions equal to all such advances to WCS. |
OPERATING LEASES
OPERATING LEASES | 6 Months Ended |
Jun. 30, 2021 | |
OPERATING LEASES | |
NOTE 5 - OPERATING LEASES | NOTE 5 - OPERATING LEASES The Company periodically enters into operating lease contracts for office space and equipment. Arrangements are evaluated at inception to determine whether such arrangements constitute a lease. Right of use assets, which we refer to as “ROU assets,” represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities were recognized on the transition date based on the present value of lease payments over the respective lease term, with the office space ROU asset adjusted for deferred rent liability. The Company has two operating leases: an office space lease with a remaining lease term of 36 months and a copier lease with a remaining lease term of one month as of June 30, 2021. All other leases are short-term leases, which for practical expediency, the Company has elected to not recognize as lease assets and lease liabilities. In accordance with ASC Topic 842, the Company has recorded lease assets of $406,024 and a related lease liability of $419,052 as of June 30, 2021. The Company recorded amortization expense of $ 61,629 for the six months ended June 30, 2021 for its leased assets. Cash paid for amounts included in the measurement of operating lease liabilities as of June 30, 2021 was $76,178. The present value of our operating lease liabilities is shown below. Maturity of Operating Lease Liabilities June 30, 2021 Remainder of 2021 $ 75,139 2022 151,333 2023 154,271 2024 77,870 2025 - Thereafter - Total lease payments 458,613 Less imputed interest (39,561 ) Present Value of Lease Liabilities $ 419,052 Operating lease liability - current 128,301 Operating lease liability – long term 290,751 As of June 30, 2021, our operating leases have a weighted average remaining lease term of 3.0 years and a weighted average discount rate of 6.25%. |
SHAREHOLDERS' EQUITY
SHAREHOLDERS' EQUITY | 6 Months Ended |
Jun. 30, 2021 | |
Shareholders' equity | |
NOTE 6 - SHAREHOLDERS' EQUITY | NOTE 6 – SHAREHOLDERS’ EQUITY Preferred Stock On February 7, 2020, CGI Cellerate RX, an affiliate of The Catalyst Group, Inc. (“Catalyst”), converted its entire holdings of its 30-month $1,500,000 convertible promissory note and 1,136,815 shares of Series F Convertible Preferred Stock into shares of the Company’s common stock. The Company issued an aggregate of 2,452,731 shares of common stock in the conversions. As of June 30, 2021, Catalyst and its affiliates controlled the voting of a total of 3,497,421 shares of the Company’s common stock, which represented 46% of the 7,612,336 shares of common stock outstanding. Common Stock At the Company’s Annual Meeting of Shareholders held on July 9, 2020, the Company approved the Restated 2014 Omnibus Long-Term Incentive Plan (the “LTIP Plan”) in which the Company’s directors, officers, employees and consultants are eligible to participate. A total of 248,234 shares had been issued under the LTIP Plan and 1,751,766 were available for issuance as of June 30, 2021. On January 18, 2021, the Company entered into an Equity Exchange Agreement (the “Exchange Agreement”), effective as of January 14, 2021, with two individuals who each owned 50% of the outstanding equity interests in Woundyne Medical, LLC (“Woundyne”). Pursuant to the Exchange Agreement, the Company acquired 100% of the issued and outstanding equity interests of Woundyne in exchange for the issuance of an aggregate of 29,536 shares of the Company’s common stock with a fair value of $1,000,000. The acquisition of the outstanding equity interests of Woundyne was accounted for as an asset acquisition. The primary asset acquired by the Company is the Woundyne software platform which allows data related to chronic and surgical wounds to be tracked, monitored, and interfaced with the software user’s electronic medical records. Woundyne has no other material assets, liabilities, or revenues. The issuance of these shares was capitalized as internal use software. The Company subsequently changed the name of Woundyne Medical, LLC to WounDerm, LLC. On February 12, 2021, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. as representative of several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 1,100,000 shares of the Company’s common stock to the Underwriters at a price to the public of $25.00 per share, less underwriting discounts and commissions (the “Offering”). Pursuant to the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to an additional 165,000 shares of common stock at the public offering price, less underwriting discounts and commissions, which the Underwriters exercised in full. The Offering, including the purchase of the 165,000 additional shares of common stock, closed on February 17, 2021. The net proceeds to the Company from the Offering were $28.9 million, after (i) giving effect to the Underwriter’s full exercise of its option to purchase additional shares of common stock, and (ii) deducting the underwriting discounts and commissions and offering expenses payable by the Company. Through an insured cash sweep service, the net proceeds have been deposited in accounts insured by the Federal Deposit Insurance Corporation. Following the closing of the Offering in February of 2021, the Company made the $750,000 Post Capital Raise Payment (as defined in the BIAKŌS License Agreement) to Rochal in the form of 20,834 shares of the Company’s common stock (see Notes 3 and 4). On July 14, 2021, the Company entered into an asset purchase agreement with Rochal, effective July 1, 2021, pursuant to which the Company purchased certain assets of Rochal. The acquired assets were purchased for an aggregate purchase price of approximately $1,000,000 consisting of (i) approximately $500,000 in cash and (ii) 14,369 shares of the Company’s common stock, representing an amount equal to $500,000 based on the average closing sale price of the Company’s common stock for the twenty trading days immediately preceding July 14, 2021. See Note 10 for more information regarding this transaction. Restricted Stock Awards During the six months ended June 30, 2021, the Company granted and issued 4,744shares of restricted common stock to one employee under the LTIP Plan. The shares are subject to certain vesting provisions and other terms and conditions set forth in the employee’s restricted stock agreement. The fair value of this award was $216,658 based on the closing price of the Company’s common stock on the grant date and is recognized as compensation expense on a straight-line basis over the vesting period of the award. Share-based compensation expense of $623,440 was recognized in selling, general and administrative expenses during the six months ended June 30, 2021, compared to $491,069 recognized during the six months ended June 30, 2020. At June 30, 2021, there was $1,001,684 of total unrecognized share-based compensation expense related to unvested share-based equity awards. Unrecognized share-based compensation expense is expected to be recognized over a weighted-average period of 0.8 years. Below is a summary of restricted stock activity for the six months ended June 30, 2021: For the Six Months Ended June 30, 2021 Weighted Average Shares Grant Date Fair Value Non-vested at beginning of period 170,178 $ 14.20 Granted 4,744 45.67 Vested (54,417 ) 15.51 Forfeited (4,786 ) 13.03 Non-vested at June 30, 2021 115,719 $ 14.92 Stock Options A summary of the status of outstanding stock options at June 30, 2021 and changes during the six-month period then ended is presented below: For the Six Months Ended June 30, 2021 Weighted Average Weighted Average Options Exercise Price Remaining Contract Life Outstanding at beginning of period 11,500 $ 6.00 Granted - - Exercised - - Forfeited - $ - Expired - - Outstanding at June 30, 2021 11,500 $ 6.00 1.5 Exercisable at June 30, 2021 11,500 $ 6.00 1.5 |
DEBT AND CREDIT FACILITIES
DEBT AND CREDIT FACILITIES | 6 Months Ended |
Jun. 30, 2021 | |
DEBT AND CREDIT FACILITIES | |
NOTE 7 - DEBT AND CREDIT FACILITIES | NOTE 7 – DEBT AND CREDIT FACILITIES Revolving Line of Credit In December 2018, Cellerate, LLC executed agreements with Cadence Bank, N.A.(“Cadence”) which provided Cellerate, LLC access to a revolving line of credit up to a maximum principal amount of $1,000,000. The line of credit was used to support the short-term working capital requirements of Cellerate, LLC. On June 21, 2019, the Company modified the revolving line of credit with Cadence to increase the maximum principal amount from $1,000,000 to $2,500,000. On October 16, 2019, the Company paid down the entire $2,200,000 balance of the revolving line of credit with cash proceeds received from a private placement of the Company’s common stock. This revolving line of credit matured on June 19, 2020. On January 15, 2021, the Company entered into a loan agreement (the “Loan Agreement”) with Cadence providing for a $2.5 million revolving line of credit. The revolving line of credit matures on January 13, 2023 and is secured by substantially all of the Company’s assets. Any amounts outstanding will bear interest of 0.75% plus the “Prime Rate” designated in the “Money Rates” section of the Wall Street Journal. Proceeds from the line of credit are to be used to provide the Company with additional working capital in support of current assets and for other general corporate purposes and may not be used for acquisitions. The line of credit contains customary representations and warranties and requires the Company to maintain compliance with certain financial covenants, including, among others, a minimum liquidity of $1,000,000 as of December 31, 2020 and March 31, 2021, a minimum Tangible Net Worth (as defined in the Loan Agreement) of $1,000,000 and, beginning with the fiscal quarter ended June 30, 2021, a minimum Interest Coverage Ratio (as defined in the Loan Agreement) of 1.5 to 1.0. The Loan Agreement also contains customary events of default. If such an event of default occurs, Cadence would be entitled to take various actions, including the acceleration of amounts due under the Loan Agreement. The Company generally may (and must, under certain circumstances) prepay all or a portion of the principal outstanding on the revolving line of credit prior to its contractual maturity. On February 11, 2021, the Company made an $800,000 draw on the revolving line of credit. On February 19, 2021, the Company paid down the entire balance of the revolving line of credit. As of June 30, 2021, there were no outstanding amounts owed by the Company under the Loan Agreement. On June 29, 2021, the Company amended the revolving line of credit with Cadence to modify certain financial covenants which included changing the initial measurement period of the minimum Interest Coverage Ratio (as defined in the Loan Agreement) from June 2021 to March 2022 (the “Modification Agreement”). In connection with this change, beginning with the fiscal quarter ended June 30, 2021 through the fiscal quarter ending December 31, 2021, the required minimum Tangible Net Worth (as defined in the Loan Agreement) was raised from $1,000,000 to $10,000,000, and the required Minimum Cash Balance (as defined in the Modification Agreement) is $3,000,000. The Company was in compliance with all of these covenants as of June 30, 2021. Beginning with the fiscal quarter ending March 31, 2022, the financial covenants return to the original terms specified in the Loan Agreement. |
INVESTMENT IN EQUITY SECURITIES
INVESTMENT IN EQUITY SECURITIES | 6 Months Ended |
Jun. 30, 2021 | |
INVESTMENT IN EQUITY SECURITIES | |
NOTE 8 - INVESTMENT IN EQUITY SECURITIES | NOTE 8 – INVESTMENT IN EQUITY SECURITIES The Company’s equity investments consist of non-marketable equity securities in privately held companies without readily determinable fair values, and are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The Company made a $500,000 long-term investment in July 2020 to purchase certain non-marketable securities consisting of 7,142,857 Series B-2 Preferred Shares of Direct Dermatology Inc. (“DirectDerm”), representing 2.9% ownership of DirectDerm at that time. Through this investment, the Company received exclusive rights to utilize DirectDerm’s technology in all acute and post-acute care settings such as skilled nursing facilities, home health, and wound clinics. The Company does not have the ability to exercise significant influence over DirectDerm’s operating and financial activities. On November 9, 2020, the Company entered into agreements to purchase certain non-marketable securities consisting of 150,000 shares of Series A Convertible Preferred Stock (the “Series A Stock”) of Precision Healing Inc. (“Precision Healing”) for an aggregate purchase price of $600,000. The Series A Stock is convertible into 150,000 shares of common stock of Precision Healing and has a senior liquidation preference relative to the common shareholders. This initial investment represented 12.6% ownership of Precision Healing’s outstanding voting securities. In February 2021, the Company invested $600,000 to purchase 150,000 additional shares of Series A Stock which is convertible into 150,000 shares of common stock of Precision Healing. This resulted in ownership of 22.4% of Precision Healing’s outstanding voting securities. With this level of significant influence, the Company transitioned to the equity method of accounting for this investment. On June 17, 2021, the Company invested $500,000 for 125,000 additional shares of Series A Stock which increased the Company’s ownership of Precision Healing’s outstanding voting securities to29.0%. For the six months ended June 30, 2021, the Company recorded $278,904 as its share of the loss from equity method investment. On June 3, 2021, the Company invested $2,084,278 to purchase 278,587 Class A Preferred Shares (the “Shares”) of Pixalere Healthcare, Inc. (“Pixalere”). The Shares are convertible into 28.6% of the outstanding equity of Pixalere. Pixalere provides a cloud-based wound care software tool that empowers nurses, specialists and administrators to deliver better care for patients. In connection with the Company’s purchase of the Shares, Pixalere granted Pixalere Healthcare USA, LLC (“Pixalere USA”), a subsidiary of the Company, a royalty-free exclusive license to use the Pixalere software and platform in the United States. In conjunction with the grant of the license, the Company issued Pixalere a 27.3% equity ownership interest in Pixalere USA valued at $93,879. The Company has reviewed the characteristics of the Shares in accordance with ASC Topic 323, Investments – Equity Method and Joint Ventures. Due to the substantive liquidation preferences of the Shares over Pixalere’s common stock, the Shares are not “in-substance” common stock, and therefore, the Company will not utilize the equity method of accounting for this investment. In accordance with ASC Topic 321, Investments - Equity Securities, this investment was reported at cost as of June 30, 2021. The following summarizes the Company’s investments: June 30, 2021 December 31, 2020 Carrying Amount Economic Interest Carrying Amount Economic Interest Equity Method Investment Precision Healing Inc. $ 1,421,096 29.04 % $ - Cost Method Investments Direct Dermatology, Inc. 500,000 2.9 % 500,000 2.9 % Precision Healing Inc. - 600,000 12.6 % Pixalere Healthcare, Inc. 2,084,278 28.6 % - Total Cost Method Investments 2,584,278 1,100,000 Total Investments $ 4,005,374 $ 1,100,000 The following summarizes the loss from the equity method investment reflected in the consolidated statements of operations: Three Months ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Investment Precision Healing Inc. $ (179,769 ) $ - $ (278,904 ) $ - Total $ (179,769 ) $ - $ (278,904 ) $ - |
RELATED PARTIES
RELATED PARTIES | 6 Months Ended |
Jun. 30, 2021 | |
RELATED PARTIES | |
NOTE 9 - RELATED PARTIES | NOTE 9 - RELATED PARTIES Payables to Related Parties The Company had outstanding payables to related parties totaling $57,507 at June 30, 2021, and 223,589 at December 31, 2020. Manufacturing and Technical Services Agreements – Related Parties On September 9, 2020, the Company executed a manufacturing agreement with Rochal. Under the terms of the manufacturing agreement, Rochal agreed to manufacture, package, and label products licensed from Rochal by the Company. The manufacturing agreement includes customary terms and conditions for the Company’s industry. The term of the agreement is for a period of five years unless extended by the mutual consent of the parties. For the six months ended June 30, 2021, the Company incurred no inventory manufacturing costs with Rochal. The Company terminated this agreement on August 12, 2021. On September 9, 2020, the Company executed a technical services agreement with Rochal. Under the terms of the technical services agreement, Rochal will provide its expertise and services on technical service projects identified by the Company for wound care, skin care and surgical site care applications. The technical services agreement includes customary terms and conditions for the Company’s industry. For the six months ended June 30, 2021, the Company incurred $234,153 of costs for Rochal technical services. The Company terminated this agreement on August 12, 2021. Rochal Asset Purchase On July 14, 2021, the Company entered into an asset purchase agreement with Rochal, effective July 1, 2021, pursuant to which the Company agreed to purchased certain assets of Rochal. The acquired assets were purchased for an aggregate purchase price of approximately $1,000,000 consisting of (i) approximately $500,000 in cash and (ii) 14,369 shares of the Company’s common stock, representing an amount equal to $500,000 based on the average closing sale price of the Company’s common stock for the twenty trading days immediately preceding July 14, 2021. After the asset purchase, Rochal now owns 95,203 shares of the Company’s common stock. Ronald T. Nixon, the Company’s Executive Chairman, is, with respect to Rochal, a director, a significant shareholder indirectly and a majority shareholder with the exercise of certain warrants. Additionally, Ann Beal Salamone, a director of the Company, is a significant shareholder, former president and current Chair of the board of directors of Rochal. See Note 10 for more information regarding this transaction. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 6 Months Ended |
Jun. 30, 2021 | |
SUBSEQUENT EVENTS | |
NOTE 10 - SUBSEQUENT EVENTS | NOTE 10 – SUBSEQUENT EVENTS On July 14, 2021, the Company entered into an asset purchase agreement with Rochal, effective July 1, 2021, pursuant to which the Company agreed to purchase certain assets of Rochal, including, among others, Rochal’s intellectual property, furniture and equipment, supplies, rights and claims, other than certain excluded assets, all as more specifically set forth in the asset purchase agreement, and assume certain liabilities upon the terms and subject to the conditions set forth in the asset purchase agreement. The acquired assets were purchased for an aggregate purchase price of approximately $1,000,000 consisting of (i) approximately $500,000 in cash and (ii) 14,369 shares of the Company’s common stock, representing an amount equal to $500,000 based on the average closing sale price of the Company’s common stock for the twenty trading days immediately preceding July 14, 2021. The purchase price is subject to post-closing adjustments pursuant to the terms of the asset purchase agreement, which such adjustments must be agreed to by the parties no later than seventy-five days after the effective date. Rochal is in the business of creating, developing and commercializing technology innovations in natural and synthetic polymers, antimicrobials and biological systems. As discussed above, the Company previously entered into product license agreements with Rochal, pursuant to which the Company acquired exclusive world-wide licenses to market, sell and further develop certain antimicrobial barrier film and skin protectant products, antimicrobial products for the prevention and treatment of microbes on the human body utilizing certain of Rochal’s patents and a debrider for human medical use to enhance skin condition or treat or relieve skin disorders. Pursuant to the asset purchase agreement, each of the foregoing licenses are being retained by Rochal and are excluded from the purchased assets. In addition, the Company previously entered into manufacturing and technical service agreements with Rochal, pursuant to which Rochal agreed to manufacture, package and label products the Company licensed from Rochal and provide certain services on technical service projects of the Company. Pursuant to the asset purchase agreement, for the three-year period after the effective date, Rochal is entitled to receive consideration for any new product relating to the business that is directly and primarily based on an invention conceived and reduced to practice by a member or members of Rochal’s science team. For the three-year period after the effective date, Rochal is also entitled to receive an amount in cash equal to twenty-five percent of the proceeds actually received for any Grant (as defined in the asset purchase agreement) by either the Company or Rochal. In addition, the Company agreed to use commercially reasonable efforts to perform Minimum Development Efforts (as defined in the asset purchase agreement) with respect to certain products under development, which if obtained, will entitle the Company to intellectual property rights from Rochal in respect of such products. In connection with the asset purchase agreement, the Company made employment offers to certain employees of Rochal on an “at will” basis, with the terms of such employment being consistent with the Company’s current employment agreements. Concurrent with the asset purchase, on July 14, 2021, the Company entered into a consulting agreement with Ms. Salamone pursuant to which Ms. Salamone will provide the Company with consulting services with respect to, among other things, writing new patents, conducting patent intelligence, and participating in certain grant and contract reporting. In consideration for the consulting services to be provided to the Company, Ms. Salamone is entitled to receive an annual consulting fee of $177,697, with payments to be paid once per month. The consulting agreement has an initial term of three years, unless earlier terminated by the Company, and is subject to renewal. The consulting agreement also contains customary provisions related to, among other things, confidentiality, and termination for cause provisions. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
Basis of Presentation | The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. Certain prior period amounts in the consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation. In the opinion of management of the Company, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six-month period ended June 30, 2021, are not necessarily indicative of the results that may be expected for the year ending December 31, 2021, or any other period. These financial statements and notes should be read in conjunction with the financial statements for each of the two years ended December 31, 2020, and December 31, 2019, included in the Company’s most recent Annual Report on Form 10-K. |
Principles of Consolidation | The accompanying unaudited consolidated financial statements include the accounts of Sanara MedTech Inc., its wholly-owned and majority-owned subsidiaries, as well as other entities in which the Company has a controlling financial interest. All significant intercompany profits, losses, transactions and balances have been eliminated in consolidation. |
Use of Estimates | The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition, and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and determined there was not a material impact on the Company’s estimates and assumptions used in preparing the unaudited consolidated financial statements as of and for the six months ended June 30, 2021. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods. |
Cash and Cash Equivalents | The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. |
Income / Loss Per Share | The Company computes income per share in accordance with Accounting Standards Codification (“ASC”) Topic 260, Earnings per Share, which requires the Company to present basic and dilutive income per share when the effect is dilutive. Basic income per share is computed by dividing income available to common shareholders by the weighted average number of shares of common stock outstanding. Diluted income per share is computed similar to basic income per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. All common stock equivalents were excluded from the current and prior period calculations, as their inclusion would have been anti-dilutive during the three and six months ended June 30, 2021 and 2020 due to the Company’s net loss. The following table summarizes the shares of common stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the three and six months ended June 30, 2021 and 2020 as such shares would have had an anti-dilutive effect: As of June 30, 2021 2020 Stock options 11,500 11,500 Unvested restricted stock 115,719 154,090 |
Revenue Recognition | The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), which the Company adopted on January 1, 2018 using the modified retrospective method. Revenues are recognized when control of the promised goods or services is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for transferring those goods or services. Revenue is recognized based on the following five step model: - Identification of the contract with a customer - Identification of the performance obligations in the contract - Determination of the transaction price - Allocation of the transaction price to the performance obligations in the contract - Recognition of revenue when, or as, the Company satisfies a performance obligation Details of this five-step process are as follows: Identification of the contract with a customer Customer purchase orders are generally considered to be contracts under ASC 606. Purchase orders typically identify specific terms of products to be delivered, create the enforceable rights and obligations of both parties, and result in commercial substance. No other forms of contract revenue recognition, such as the completed contract or percentage of completion methods, were utilized by the Company in either 2020 or 2021. Performance obligations The Company’s performance obligation is generally limited to delivery of the requested items to its customers at the agreed upon quantities and prices. Determination and allocation of the transaction price The Company has established prices for its products. These prices are effectively agreed to when customers place purchase orders with the Company. Rebates and discounts, if any, are recognized in full at the time of sale as a reduction of net revenue. Allocation of transaction prices is not necessary where one performance obligation exists. Recognition of revenue as performance obligations are satisfied Product revenues are recognized when the products are delivered, and control of the goods and services passes to the customer. Disaggregation of Revenue Revenue streams from product sales and royalties are summarized below for the six months ended June 30, 2021 and 2020. All revenue was generated in the United States; therefore, no geographical disaggregation was necessary. Six Months Ended June 30, 2021 2020 Product sales revenue $ 11,186,069 $ 6,391,014 Royalty revenue 100,500 100,500 Total Revenue $ 11,286,569 $ 6,491,514 The Company recognizes royalty revenue from a development and licensing agreement between BioStructures, LLC and the Company. The Company records revenue each calendar quarter as earned per the terms of the agreement which stipulates that the Company will receive quarterly royalty payments of at least $50,250. Under the terms of the development and license agreement, royalties of 2.0% are recognized on sales of products containing the Company’s patented resorbable bone hemostasis. The minimum annual royalty due to the Company is $201,000 per year throughout the life of the patent which expires in 2023. These royalties are payable in quarterly installments of $50,250. To date, royalties related to this development and licensing agreement have not exceeded the annual minimum of $201,000 ($50,250 per quarter). |
Contract Assets and Liabilities | The Company does not have any contract assets or contract liabilities. |
Allowance for Doubtful Accounts | The Company establishes an allowance for doubtful accounts to ensure accounts receivable are not overstated due to uncollectible accounts. The Company recorded bad debt expense of $51,536 and $30,000during the six months ended June 30, 2021 and 2020, respectively. The allowance for doubtful accounts was $120,273 at June 30, 2021 and $64,989 at December 31, 2020. Bad debt reserves are maintained based on a variety of factors, including the length of time receivables are past due and a detailed review of certain individual customer accounts. The Company also establishes other allowances to ensure accounts receivable are not overstated due to customer rebates and product returns. These allowances totaled $18,144 at June 30, 2021 and $35,200 at December 31, 2020. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. The Company considered the impact of COVID-19 in its analysis of receivables and determined its accounts receivable allowances were appropriate at June 30, 2021. |
Inventories | Inventories are stated at the lower of cost or net realizable value, with cost computed on a first-in, first-out basis. Inventories consist of finished goods and related packaging components. The Company recorded inventory obsolescence expense of $29,834 the six months ended June 30, 2021 and $75,422 the six months ended June 30, 2020. The allowance for obsolete and slow-moving inventory had a balance of $295,841 at June 30, 2021, and $276,603 at December 31, 2020. The Company considered the impact of COVID-19 on its recorded value of inventory and determined no adjustment was necessary as of June 30, 2021. |
Property and Equipment | Property and equipment are stated at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets, ranging from three to ten years. Below is a summary of property and equipment for the periods presented: June 30, December 31, 2021 2020 Computers $ 98,140 $ 87,252 Office equipment 22,598 22,597 Furniture and fixtures 209,746 205,871 Leasehold improvements 2,030 2,030 Internal use software 1,485,530 485,530 Capital in progress 10,682 - 1,828,726 803,280 Less accumulated depreciation (159,732 ) (124,691 ) Property and equipment, net $ 1,668,994 $ 678,589 Depreciation expense related to property and equipment was $35,040 for the six months ended June 30, 2021, and $33,227 for the six months ended June 30, 2020. The Company considered the impact the COVID-19 pandemic may have had on the carrying value of its property and equipment and determined that no impairment loss had occurred as of June 30, 2021. The Company will continue to assess the COVID-19 pandemic’s impact on its business including any indicators of impairment of property and equipment. |
Internal Use Software | The Company accounts for costs incurred to develop computer software for internal use in accordance with ASC Topic 350-40, Intangibles – Goodwill and Other. The Company capitalizes the costs incurred during the application development stage, which generally includes third-party developer fees to design the software configuration and interfaces, coding, installation, and testing. The Company begins capitalization of qualifying costs when both the preliminary project stage is completed, and management has authorized further funding for the completion of the project. Costs incurred during the preliminary project stage along with post implementation stages of internal-use computer software are expensed as incurred. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Capitalized development costs are classified as property and equipment, net in the consolidated balance sheets and are amortized over the estimated useful life of the software, which is generally five to seven years. |
Intangible Assets | Intangible assets are stated at cost of acquisition less accumulated amortization and impairment loss, if any. Cost of acquisition includes purchase price and any cost directly attributable to bringing the asset to its working condition for the intended use. The Company amortizes its intangible assets on a straight-line basis over the useful life of the respective assets which is generally the life of the related patents (if applicable). See Note 3 |
Impairment of Long-Lived Assets | Long-lived assets, including certain identifiable intangibles held and to be used by the Company, are reviewed for impairment whenever events or changes in circumstances, including the COVID-19 pandemic, indicate that the carrying amount of such assets may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows and the estimated liquidation value of such long-lived assets and provides for impairment if such undiscounted cash flows are insufficient to recover the carrying amount of the long-lived assets. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market values, undiscounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value. No impairment was recorded during the six months ended June 30, 2021 and 2020. |
Investment in Equity Securities | The Company’s equity investments consist of non-marketable equity securities in privately held companies without readily determinable fair values, and are reported at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The Company applies the equity method of accounting to investments when it has significant influence, but not controlling interest, in the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as ownership interest, representation on the board of directors, participation in policy-making decisions and material intercompany transactions. The Company’s proportionate share of the net income (loss) resulting from these investments is reported under the line item captioned “Share of losses from equity method investment” in our consolidated statements of operations. The Company’s equity method investments are adjusted each period for the Company’s share of the investee’s income or loss and dividend paid, if any. The Company classifies distributions received from equity method investments using the cumulative earnings approach on the consolidated statements of cash flows. The Company has reviewed the carrying value of its investments and has determined there was no impairment or observable price changes as of June 30, 2021. |
Fair Value Measurement | As defined in ASC Topic 820, Fair Value Measurement (“ASC 820”), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses approximate fair value because of the short-term nature of these instruments. The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis. |
Income Taxes | Income taxes are accounted for under the asset and liability method, whereby deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. |
Advertising Expense | In accordance with ASC Topic No. 720-35-25-1, the Company recognizes advertising expenses the first time the advertising takes place. Advertising expenses are expensed as incurred. |
Share-based Compensation | The Company accounts for stock-based compensation to employees and nonemployees in accordance with Accounting Standards Update (“ASU”) 2018-07 Topic 718. Stock-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as expense over the stipulated vesting period, if any. The Company estimates the fair value of stock-based payments using the Black-Scholes option-pricing model for common stock options and warrants, and the closing price of the Company’s common stock for common stock issuances. |
Research and Development Costs | Research and development expenses include costs for contracted services related to improvements to manufacturing processes, enhancements to the Company’s currently available products, and additional investments in the product and platform development pipeline. The Company expenses research and development costs as incurred. |
Recently Adopted Accounting Pronouncements | In December 2019, the Financial Accounting Standards Board issued ASU 2019-12, Simplifications to Accounting for Income Taxes, which removes certain exceptions to the general principles of Topic 740 and adds guidance to reduce complexity in accounting for income taxes. The ASU is effective for annual and interim periods in fiscal years beginning December 15, 2020. The adoption of this standard did not have a material effect on the Company’s consolidated financial statements. |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
Schedule of common stock potentially issuable | As of June 30, 2021 2020 Stock options 11,500 11,500 Unvested restricted stock 115,719 154,090 For the Six Months Ended June 30, 2021 Weighted Average Weighted Average Options Exercise Price Remaining Contract Life Outstanding at beginning of period 11,500 $ 6.00 Granted - - Exercised - - Forfeited - $ - Expired - - Outstanding at June 30, 2021 11,500 $ 6.00 1.5 Exercisable at June 30, 2021 11,500 $ 6.00 1.5 |
Schedule of Revenue from product sales and royalties | Six Months Ended June 30, 2021 2020 Product sales revenue $ 11,186,069 $ 6,391,014 Royalty revenue 100,500 100,500 Total Revenue $ 11,286,569 $ 6,491,514 |
Schedule of Property and equipment | June 30, December 31, 2021 2020 Computers $ 98,140 $ 87,252 Office equipment 22,598 22,597 Furniture and fixtures 209,746 205,871 Leasehold improvements 2,030 2,030 Internal use software 1,485,530 485,530 Capital in progress 10,682 - 1,828,726 803,280 Less accumulated depreciation (159,732 ) (124,691 ) Property and equipment, net $ 1,668,994 $ 678,589 |
INTANGIBLE ASSETS (Tables)
INTANGIBLE ASSETS (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
INTANGIBLE ASSETS | |
Finite-lived intangible assets | June 30, 2021 December 31, 2020 Accumulated Accumulated Cost Amortization Net Cost Amortization Net Product Licenses $ 4,193,879 $ (417,519 ) $ 3,776,360 $ 3,350,000 $ (264,909 ) $ 3,085,091 Patent 510,310 (510,310 ) - 510,310 (510,310 ) - Software and Other 64,464 (55,637 ) 8,827 64,464 (51,889 ) 12,575 Total $ 4,768,653 $ (983,466 ) $ 3,785,187 $ 3,924,774 $ (827,108 ) $ 3,097,666 |
Estimated remaining amortization expense | Remainder of 2021 $ 172,769 2022 343,123 2023 338,043 2024 338,043 2025 338,043 Thereafter 2,255,166 Total $ 3,785,187 |
OPERATING LEASES (Tables)
OPERATING LEASES (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
OPERATING LEASES | |
Maturity of operating lease liabilities | June 30, 2021 Remainder of 2021 $ 75,139 2022 151,333 2023 154,271 2024 77,870 2025 - Thereafter - Total lease payments 458,613 Less imputed interest (39,561 ) Present Value of Lease Liabilities $ 419,052 Operating lease liability - current 128,301 Operating lease liability – long term 290,751 |
SHAREHOLDERS' EQUITY (Tables)
SHAREHOLDERS' EQUITY (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Shareholders' equity | |
Restricted stock activity | For the Six Months Ended June 30, 2021 Weighted Average Shares Grant Date Fair Value Non-vested at beginning of period 170,178 $ 14.20 Granted 4,744 45.67 Vested (54,417 ) 15.51 Forfeited (4,786 ) 13.03 Non-vested at June 30, 2021 115,719 $ 14.92 |
INVESTMENT IN EQUITY SECURITI_2
INVESTMENT IN EQUITY SECURITIES (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
INVESTMENT IN EQUITY SECURITIES | |
Investments | June 30, 2021 December 31, 2020 Carrying Amount Economic Interest Carrying Amount Economic Interest Equity Method Investment Precision Healing Inc. $ 1,421,096 29.04 % $ - Cost Method Investments Direct Dermatology, Inc. 500,000 2.9 % 500,000 2.9 % Precision Healing Inc. - 600,000 12.6 % Pixalere Healthcare, Inc. 2,084,278 28.6 % - Total Cost Method Investments 2,584,278 1,100,000 Total Investments $ 4,005,374 $ 1,100,000 |
Loss from equity method investment | Three Months ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Investment Precision Healing Inc. $ (179,769 ) $ - $ (278,904 ) $ - Total $ (179,769 ) $ - $ (278,904 ) $ - |
SUMMARY OF SIGNIFICANT ACCOUN_4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Unvested Restricted Stock | ||
Anti-dilutive securities | 115,719 | 154,090 |
Stck Option [Member] | ||
Anti-dilutive securities | 11,500 | 11,500 |
SUMMARY OF SIGNIFICANT ACCOUN_5
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Total revenue | $ 6,277,133 | $ 11,286,569 | $ 2,967,183 | $ 6,491,514 | $ 11,286,569 | $ 6,491,514 |
Royalty Revenue | ||||||
Total revenue | 100,500 | 100,500 | ||||
Product Sales Revenue | ||||||
Total revenue | $ 11,186,069 | $ 6,391,014 |
SUMMARY OF SIGNIFICANT ACCOUN_6
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Property and equipment, gross | $ 1,828,726 | $ 803,280 |
Less accumulated depreciation | (159,732) | (124,691) |
Property and equipment, net | 1,668,994 | 678,589 |
Capital in progress | ||
Property and equipment, gross | 10,682 | 0 |
Computers | ||
Property and equipment, gross | 98,140 | 87,252 |
Office Equipment | ||
Property and equipment, gross | 22,598 | 22,597 |
Furniture and Fixtures | ||
Property and equipment, gross | 209,746 | 205,871 |
Leasehold Improvements | ||
Property and equipment, gross | 2,030 | 2,030 |
Internal use software | ||
Property and equipment, gross | $ 1,485,530 | $ 485,530 |
SUMMARY OF SIGNIFICANT ACCOUN_7
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2021 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||
Bad debt expense | $ 51,536 | $ 30,000 | ||
Allowance for doubtful accounts | 120,273 | $ 64,989 | ||
Inventory obsolescence | 29,834 | 75,422 | ||
Other allowances | 138,417 | 35,200 | ||
Allowance for obsolete and slow-moving inventory | 295,841 | $ 276,603 | ||
Depreciation expense | 35,040 | 33,227 | ||
Royalty payments (Quarterly) | $ 50,250 | |||
Royalty due (Annually) | $ 55,000 | $ 50,000 | ||
Percentage of sale recognised | 2.00% |
INTANGIBLE ASSETS (Details)
INTANGIBLE ASSETS (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Cost | $ 4,768,653 | $ 3,924,774 |
Accumulated amortization | 983,466 | (827,108) |
Net | 3,785,187 | 3,097,666 |
Product License | ||
Cost | 4,193,879 | 3,350,000 |
Accumulated amortization | (417,519) | (264,909) |
Net | 3,776,360 | 3,085,091 |
Patent | ||
Cost | 510,310 | 510,310 |
Accumulated amortization | (510,310) | (510,310) |
Net | 0 | 0 |
Software and Other | ||
Cost | 64,464 | 64,464 |
Accumulated amortization | (55,637) | (51,889) |
Net | $ 8,827 | $ 12,575 |
INTANGIBLE ASSETS (Details 1)
INTANGIBLE ASSETS (Details 1) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
INTANGIBLE ASSETS | ||
Remainder of 2021 | $ 172,769 | |
2022 | 343,123 | |
2023 | 338,043 | |
2024 | 338,043 | |
2025 | 338,043 | |
Thereafter | 2,255,166 | |
Total | $ 3,785,187 | $ 3,097,666 |
INTANGIBLE ASSETS (Details Narr
INTANGIBLE ASSETS (Details Narrative) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
INTANGIBLE ASSETS | ||
Weighted-average amortization period | 12 years 4 months 24 days | |
Amortization expense | $ 156,358 | $ 94,499 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details Narrartive) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
COMMITMENTS AND CONTINGENCIES | ||
Royalties due | $ 404,220 | $ 210,220 |
Royalty expense | $ 55,000 | $ 50,000 |
OPERATING LEASES (Details)
OPERATING LEASES (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
OPERATING LEASES | ||
Remainder of 2021 | $ 75,139 | |
2022 | 151,333 | |
2023 | 154,271 | |
2024 | 77,870 | |
2025 | 0 | |
Thereafter | 0 | |
Total lease payments | 458,613 | |
Less imputed interest | (39,561) | |
Present value of lease liabilities | 419,052 | |
Operating lease liability - current | 128,301 | $ 125,587 |
Operating lease liability - long term | $ 290,751 | $ 355,797 |
OPERATING LEASES (Details Narra
OPERATING LEASES (Details Narrative) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Dec. 31, 2020 | |
OPERATING LEASES | ||
Lease assets | $ 406,024 | $ 467,653 |
Present value of lease liabilities | 419,052 | |
Amortization of leased asset | 61,629 | |
Cash paid for amounts included in measurement of operating lease liabilities | $ 76,178 | |
Weighted average remaining lease term | 3 years | |
Weighted average discount rate | 6.25% |
SHAREHOLDERS EQUITY (Details)
SHAREHOLDERS EQUITY (Details) | 6 Months Ended |
Jun. 30, 2021$ / sharesshares | |
Shareholders' equity | |
Non-vested shares, beginning | shares | 170,178 |
Granted | shares | 4,744 |
Vested | shares | (54,417) |
Forfeited | shares | (4,786) |
Non-vested shares, ending | shares | 115,719 |
Weighted average grant date fair value, beginning | $ / shares | $ 14.20 |
Granted | $ / shares | 45.67 |
Vested | $ / shares | 15.51 |
Forfeited | $ / shares | 13.03 |
Weighted average grant date fair value, ending | $ / shares | $ 14.92 |
SHAREHOLDERS EQUITY (Details 1)
SHAREHOLDERS EQUITY (Details 1) | 6 Months Ended |
Jun. 30, 2021$ / sharesshares | |
Shareholders' equity | |
Number of options outstanding, beginning | shares | 11,500 |
Granted | shares | 0 |
Exercised | shares | 0 |
Expired | shares | 0 |
Number of options outstanding, ending | shares | 11,500 |
Number of options exercisable | shares | 11,500 |
Weighted average exercise price outstanding, beginning | $ 6 |
Granted | 0 |
Exercised | 0 |
Forfeited | 0 |
Expired | 0 |
Weighted average exercise price outstanding, ending | 6 |
Weighted average exercise price exercisable | $ 6 |
Weighted average remaining contract life outstanding | 1 year 6 months |
Weighted average remaining contract life exercisable | 1 year 6 months |
SHAREHOLDERS EQUITY (Details Na
SHAREHOLDERS EQUITY (Details Narrative) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Restricted common stock granted | 4,744 | |
Fair value of restricted common stock granted | $ 216,658 | |
Share-based compensation expense | 623,440 | $ 491,069 |
Unrecognized share-based compensation expense | $ 1,001,684 | |
Unrecognized share-based compensation expense period for recognition | 1 year 1 month 6 days | |
July 14, 2021 [Member] | Asset purchase agreement [Member] | ||
Acquired assets, Cash | $ 500,000 | |
Acquired assets, Aggregate purchase price | $ 1,000,000 | |
Acquired assets, Common stock, shares purchased | 14,369 | |
Acquired assets, Common stock value based on the average closing sale price | $ 500,000 |
DEBT AND CREDIT FACILITIES (Det
DEBT AND CREDIT FACILITIES (Details Narrative) - USD ($) | Jan. 15, 2021 | Jun. 29, 2021 | Oct. 16, 2019 | Jun. 21, 2019 | Jun. 30, 2021 | Jun. 30, 2021 | Jun. 30, 2020 | Mar. 31, 2021 | Feb. 11, 2021 | Dec. 31, 2020 |
Revolving line of credit, Increase in principal amount | $ 2,500,000 | |||||||||
Revolving line of credit, Cash proceeds | $ 2,200,000 | $ 800,000 | $ 0 | |||||||
Line of credit, Principal amount | $ 1,000,000 | $ 1,000,000 | ||||||||
Revolving line of credit | $ 800,000 | |||||||||
Loan Agreement [Member] | ||||||||||
Revolving line of credit | $ 2,500,000 | |||||||||
Line of credit, Maturity date | January 13, 2023 | |||||||||
Line of credit, interest rate | 0.75% | |||||||||
Line of credit, Minimum liquidity amount | $ 1,000,000 | $ 1,000,000 | ||||||||
Line of credit, Minimum tangible net worth | $ 1,000,000 | |||||||||
Line of credit, Interest Coverage Ratio | 1.5 to 1.0 | |||||||||
Line of credit, Increase in minimum tangible net worth | $ 10,000,000 | |||||||||
Modification Agreement [Member] | ||||||||||
Line of credit, Minimum cash balance required | $ 3,000,000 |
INVESTMENT IN EQUITY SECURITI_3
INVESTMENT IN EQUITY SECURITIES (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Cost method investment | $ 2,584,278 | $ 1,100,000 |
Total investments | 4,005,374 | 1,100,000 |
Equity method investment | 1,421,096 | 0 |
Precision Healing Inc. [Member] | ||
Cost method investment | 0 | 600,000 |
Equity method investment | $ 1,421,096 | $ 0 |
Economic interest | 29.04% | 12.60% |
Pixalere Healthcare, Inc [Member] | ||
Cost method investment | $ 2,084,278 | |
Economic interest | 28.60% | |
Direct Dermatology, Inc. [Member] | ||
Cost method investment | $ 500,000 | $ 500,000 |
Economic interest | 2.90% | 2.90% |
INVESTMENT IN EQUITY SECURITI_4
INVESTMENT IN EQUITY SECURITIES (Details 1) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Loss from the equity method investment | $ (179,769) | $ 0 | $ (278,904) | $ 0 |
Precision Healing Inc. [Member] | ||||
Loss from the equity method investment | $ (179,769) | $ 0 | $ (278,904) | $ 0 |
INVESTMENT IN EQUITY SECURITI_5
INVESTMENT IN EQUITY SECURITIES (Details Narrative) - USD ($) | Jun. 03, 2021 | Nov. 09, 2020 | Jun. 17, 2021 | Feb. 28, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Jul. 31, 2021 | Jul. 03, 2021 | Dec. 31, 2020 |
Loss from the equity method investment | $ (179,769) | $ 0 | $ (278,904) | $ 0 | ||||||||
Long-term investment | $ 4,005,374 | $ 4,005,374 | $ 1,100,000 | |||||||||
common stock, shares issued value | $ 28,939,257 | |||||||||||
Series A Stock [Member] | ||||||||||||
common stock, shares issued | 278,587 | 150,000 | 125,000 | 150,000 | ||||||||
common stock, shares issued value | $ 600,000 | |||||||||||
Series A Convertible shares, common stock | 150,000 | |||||||||||
Ownership percentage | 28.60% | 12.60% | 29.00% | 22.40% | ||||||||
Investments | $ 2,084,278 | $ 500,000 | $ 600,000 | |||||||||
Subsequent Event [Member] | ||||||||||||
Long-term investment | $ 500,000 | |||||||||||
Non-marketable securities | $ 7,142,857 | |||||||||||
Pixalere USA [Member] | ||||||||||||
Equity ownership interest, Value | $ 93,879 |
RELATED PARTIES (Details Narrat
RELATED PARTIES (Details Narrative) - USD ($) | Jul. 14, 2021 | Jun. 30, 2021 | Dec. 31, 2020 |
Payables to related party | $ 57,507 | $ 223,589 | |
Technical services | $ 234,153 | ||
Subsequent Event [Member] | |||
Assets acquired | $ 1,000,000 | ||
Common stock, shares issued | 14,369 | ||
Cash | $ 500,000 | ||
Asset Purchase Agreement [Member] | Subsequent Event [Member] | |||
Assets acquired | $ 1,000,000 | ||
Common stock, shares issued | 14,369 | ||
Cash | $ 500,000 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] | Jul. 14, 2021USD ($)shares |
Assets acquired | $ 1,000,000 |
Cash | $ 500,000 |
Common stock, shares issued | shares | 14,369 |
Consulting fee | $ 177,697 |